Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaviFUS System + Bevacizumab in Recurrent Glioblastoma Multiforme
NCT04446416Completed
- Sponsor
- NaviFUS
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial in glioblastoma multiforme (GBM), sponsored by NaviFUS. Primary endpoints: Adverse Events at 38 weeks and Progression-Free Survival at 6 months. Started Jul 2020; status: completed.
02
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04446416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446416.